chrisvoncsefalvay/vaers-outcomes huggingface dataset:
About 15 min after the shot, I started to feel dizzy, but the BP was just little higher than my normal - 120-130/90 - 100 with pulse 70-88. No epi was administered and my husband (came with me due to my history of hypertensive anaphylactic reaction to an allergy shot) drove us home.  By the time we got home, I was nauseated and my husband could see some fluid in my ear with an otoscope. He called an allergist office and the medrol pack was prescribed (also prescribed at the time of anaphylaxis previously).  About 16 hours post-vaccine, I felt chills, then, low grade fever, headaches, bodyaches and heaviness/fatigue followed.  Those symptoms came and went a few times. By 48 hours pose dose, all flu-like symptoms dissappeared.
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant medications were not reported. On 27-MAY-2-16, the patient was vaccinated with improperly stored VARIVAX lot # L043622, expiry date 03-NOV-2017 (dose, route and site of administration were not reported) and M-M-R II, lot # L027434, expiry date 22-JUL-2017 (dose, route and site of administration were not reported) which was also improperly stored. There were no adverse effects reported. Administered vaccines experienced following temperature excursions: on 14-MAY-2016 6 degrees Fahrenheit (F) for 1.5 hours and on 20-MAY-2016 5.9 degrees F for 5.5 hours. The freezer returned to proper range in between all excursions. Data logger was involved. This is one of several cases received from the same source. Additional information has been requested.
On 12/30/2000 the patient developed 10 lesions. Subsequently the patient recovered on 01/07/2001. No further information is available.
changes in the taste; changes in the smell; Adrenaline rash 30 minutes after receiving the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of TASTE DISORDER (changes in the taste), PAROSMIA (changes in the smell) and RASH (Adrenaline rash 30 minutes after receiving the vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, the patient experienced TASTE DISORDER (changes in the taste), PAROSMIA (changes in the smell) and RASH (Adrenaline rash 30 minutes after receiving the vaccine). At the time of the report, TASTE DISORDER (changes in the taste), PAROSMIA (changes in the smell) and RASH (Adrenaline rash 30 minutes after receiving the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Patient received 0.25 mL as their 1st dose instead of full dose; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (Patient received 0.25 mL as their 1st dose instead of full dose) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 081F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On 30-Nov-2021, the patient experienced ACCIDENTAL UNDERDOSE (Patient received 0.25 mL as their 1st dose instead of full dose). On 30-Nov-2021, ACCIDENTAL UNDERDOSE (Patient received 0.25 mL as their 1st dose instead of full dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. Treatment medication was not provided by the reporter.
Feeling hot, turning red, difficulty breathing, chest pains and really feeling rotten. The doctor did an EKG. Have to check with them for rest of treatment.
Two patients that received Shingrix first dose almost a year ago; This case was reported by a nurse via call center representative and described the occurrence of incomplete course of vaccination in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received almost a year ago on 17th January 2020).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time of reporting, patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. The reporter consented to follow up by email. This case has been linked with US2021084266, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021084266:Same reporter. Pt 1.
April 1st.  Experienced flu-like symptoms including headache, mild muscular aches, fever/chills and lethargy, low energy. Started mid morning, improving by 6 pm.  Fine by next morning. April 7th.  Late morning noticed itching on upper right arm at injection site.  At 4 pm saw redness and raised skin there.  Very itchy rash continued through until today (April 8th).  Rash looks improved but still itching.
Patient reported itching  on arm and leg gave patient a diphenhydramine 50mg asked to sit and observed patient for 30 minutes for sign of allergy getting worse, did not get worse advised patient to urgent care or ER, patient got a ride to urgent care per patient
I tested positive for Covid on 01/16/22 and from 01/16/22-01/26/2022 I had what felt like a sinus infection, I had extreme tiredness and dizziness, and had a loss of smell and taste.
Patient in office with sibling, both receiving multiple vaccines. Accidental admin from wrong tray, resulting in patient receiving 2 doses of HPV in one day. Patient receiving total now of 4 HPV doses, 3 and 4 on same day. Patient remained in office for 15" wait after vaccines, no stated problems.
the patient is 62 years old and he received a dose of GARDASIL 9 six months ago; This spontaneous report was received from a consumer as a 62 year old male patient. The patient's concurrent conditions, past medical history and concomitant medications were not reported.  In approximately July 2019 (reported as 6 months ago), the patient was vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9) (dose, frequency, route, lot/batch # and expiration date were not provided)  for prophylaxis (product administered to patient of inappropriate age).
Initial and follow-up information has been received from the Merck Pregnancy Registry via a registered nurse concerning a 19 year old female with depression and a history of a normal 40 week full term delivery who on 08-AUG-2007 was vaccinated intramuscularly with a 0.5 ml first dose of Gardasil (Lot #657617/0384U).  Concomitant therapy included DEPO-PROVERA, fluoxetine HCl and an unspecified sleeping pill.  Subsequently, the patient was pregnant.  The patient had been utilizing DEPO-PROVERA so she did not experience regular menstrual cycles.  The patient's last menstrual period was estimated as 24-JUL-2007 from physical exam and the estimated date of delivery was on 29-APR-2008.  It was mentioned that the patient patient suspected pregnancy due to the developing nausea and vomiting.  It was on 10-SEP-2007 after a visit to hospital a urine pregnancy test was performed, results positive.  Also, the nurse mentioned that patient had a visit to the hospital (no admission) during the first week of September 2007.  The patient experienced numbness on the right side in her hands and lower extremities.  She could not move or talk.  Unspecified bloodwork was taken, results were not disclosed.  The patient's symptoms resolved and she was sent home.  There was no diagnosis or explanation to the reason for the patient's numbness.  Patient's outcome related to pregnancy was unknown.  Additional information has been requested. Follow-up phone call information has been received from a registered nurse who reported that the patient delivered a healthy, normal baby on 19-APR-2008. No additional information is expected.
When the RN gave me the injection, the needle went in along with an unknown amount of the moderna vaccine. The hub was not tightly secured to the syringe and as a result the remaining vaccine ran down my arm. She, the administering RN, consulted with another person and they decided I should receive another full dose vaccine immediately that day. She then administered a full dose of the Moderna vaccine.
Acute Inflammatory Demyelinating Polyneuropathy Hospitalized 4/26/21 with severe leg weakness/sensory loss on exam; Also developed a left sided bells palsy the week of 4/26/21 MRI T and LS spine negative;CT Brain negative; Lyme test negative, CMV,EBV,HIV negative; B12,TSH normal Lumbar Puncture-Increased CSF Protein, lymphocytic pleocytosis, oligoclonal band Treated with IV IgG infusions x 5 days -Initial partial improvement in leg strength after 1 week Gradual improvement over a few months-mostly recovered; however modest cognitive deficit remains
While waiting the 15 minute after vaccination the Patient noticed a "tingling" feeling in throat about 5 minutes after vaccine was given.  Time: 0930 - Oxygen Saturation was 98% Pulse Rate 100.  Patient stated that the feeling went away and then came back.   Time: 0938 - Again vital signs were taken BP 156/88 Oxygen Saturation 100% Pulse Rate 83.  Time: 0942 - 50 mg of Benadryl PO were given with water at this time.  Patient was taken to ER for evaluation.
Information has been received from a medical technologist concerning a 1 year old male who on 3/12/99 was vaccinated and on approximately, 4/6/99, he developed atypical rash and was seen by a physician on 4/7/99. The reporter expressed concern with the lot #. Two additional pts were reported with similar incident after having been vaccinated with the same lot #. Additional information has been requested.
Patient report shaking, fever of 104.0, following PREVNAR 13 vaccination, states he presented to hospital ER for evaluation. Reports multiple lab work performed, states he was discharged  the same day. Patient reports joint pain on left arm, shoulder, hand, elbow pain, states location of vaccination, states it also feels like someone punched me real hard where they gave me the shot.
I experienced a breakthrough case of COVID after receiving the vaccine. I had a sore throat, slight cough, brief fever, body aches, and fatigue. During my telehealth visit with my doctor, I received a prescription for Paxlovid. I was instructed to isolate for 5 days and to wear a mask around people.
Headaches, fatigue and co fusion for about 2 weeks. Fatigue lasted about 3 months.
Modern COVID-19 Vaccine EUA I received my COVID vaccine at 7:00pm on 2/22/2021.  At 1:00 am 2/23/2021 I woke up to use the restroom.  I fainted and cut my forehead in the fall.  I was shaking uncontrollably following this.  My husband bandaged my forehead and checked me for a concussion.  Sometime after 2am I realized I was in atrial fibrillation.  I have a Kardia app that confirmed this.  I tried at home methods to go back in rhythm.  At 8am I called my cardiologist.  He advised me to go to the emergency room.  At this time the Kardia app indicated I was no longer in Afib but still had a fast heartbeat.  At the emergency room I had a normal EKG, CAT scan, blood work and chest X-ray and went home about 11am.
A non-serious spontaneous report of administration of the full FLUMIST dose in one nostril was received from a pharmacist concerning a five-year-old female subsequent to the administration of FLUMIST. Relevant medical history and concomitant medications were not reported. On 18-Nov-2009, the patient received a full dose of FLUMIST into one nostril. There was no adverse event associated with this vaccination error, therefore treatment and reporter/sponsor causality assessments are not applicable and the event is considered to be resolved.
Mom took child to ER 16JAN91 for red raised - painful injection site, fever to 101 & headache.
This case was reported by a nurse via sales rep and described the occurrence of shingles in a 72-year-old female patient who received SHINGRIX. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a week after receiving SHINGRIX, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown. It was unknown if the reporter considered the shingles to be related to SHINGRIX. Additional details were provided as follows: This case was reported by a registered nurse and family nurse practitioner student, they noted a patient who received SHINGRIX and was diagnosed with shingles within the same week she received the vaccine, no exact date was provided. Hospitalization was not noted for treatment of shingles. The date of birth of the patient, initials of patient, pharmacy that administered SHINGRIX, anatomical location of injection, lot number and expiration date, dose administered, date of vaccination, concomitant vaccines, concomitant medications, outcome of diagnosis details were not known.
Immunocompromised patient received the booster dose (half dose) after 2 primary doses; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (Immunocompromised patient received the booster dose (half dose) after 2 primary doses) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (Immunocompromised patient received the booster dose (half dose) after 2 primary doses). At the time of the report, ACCIDENTAL UNDERDOSE (Immunocompromised patient received the booster dose (half dose) after 2 primary doses) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. It was reported that the patient received the booster dose,half dose after 2 primary doses. No treatment medications were reported.
Patient received his first dose of COVID-19 vaccination on 04/09/2021 Pfizer, the second dose was given on 04/28/2021 was a COVID-19 Moderna vaccine. Patient with no symptoms, or side effects.
Fever 101.3; mild headache; body ache; chills; fatigue; This is a spontaneous report received from a contactable Other Health Care Professional (patient herself) of 39-years-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, lot number and Expiration date was not reported), via intramuscular route of administration in Arm Left on 10Feb2021 09:00 and first dose on 27Jan2021 both as single dose for COVID-19 immunization. The patient medical history was not reported and no known allergies.Prior to vaccination, patient was not diagnosed with COVID-19 and did not test for covid post vaccination. Concomitant medications included acetylsalicylic acid (BABY ASPIRIN); magnesium (MAGNESIUM); colecalciferol, fish oil (OMEGASAN 3); zinc (ZINC); ascorbic acid, calcium carbonate, calcium pantothenate, calcium phosphate, chromium, cyanocobalamin, folic acid, magnesium carbonate, magnesium hydroxide, manganese gluconate, nicotinic acid, potassium bicarbonate, potassium carbonate, potassium phosphate dibasic, pyridoxine hydrochloride, quercetin, riboflavin sodium phosphate, sodium bicarbonate, sodium phosphate, thiamine hydrochloride, thioctic acid, zinc ascorbate (EMERGEN C); ergocalciferol (VIT D). on 10Feb2021 19:30, patient experienced the fever 101.3, mild headache, body ache, chills and fatigue. Patient did not received treatment for events. The patient underwent lab tests and procedures which included body temperature: 101.3 on 10Feb2021. The outcome for all the events was recovering.
HIGH FEVER; 103 DEGREES (ARMPIT, DIGITAL) 3 DAYS AND COUNTING...
Received pneumovax vaccine approx 11:00am. By 19:00 experienced severe pain in Left arm. Did not see any redness or swelling. Denies fever. On scale of 1-10, says pain was a "3". Says pain is easing up and much better today 11/3/06.
will like to know if the patient has to restart the series; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 52-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 6th March 2022 in left arm with batch number 42YY3 and expiry date 28th May 2024).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: will like to know if the patient has to restart the series). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date: 25-MAY-2023 The pharmacist would like to know if the patient had to restart the series. The reporter consented to follow up. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.
Fainted; Diarrhea; Nausea; Warm body temperature; A spontaneous report was received from a consumer, regarding herself, a 82-year-old, female consumer who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced fainted, diarrhea, nausea and warm body temperature.  The patient's medical history reported included ulcerative colitis. Concomitant product use was not provided.  On 04 Feb 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (lot Number: 038K20A) intramuscularly for prophylaxis of COVID-19 infection.   On 04 Feb 2021, in the evening, after receiving the vaccine, the patient was fainted and started to experience diarrhea, nausea and warm body temperature. The event fainted was considered to be medically significant. Treatment for the events not provided.  Action taken with the second dose of mRNA-1273 in response to the events were not reported.   The outcome for the events, fainted, diarrhea, nausea and warm body temperature were resolved on 05 Feb 2021.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the onset date of the events, a causal relationship cannot be excluded.
Hives; Itchy area of injection; hot to touch; Redness at site for injection; Soreness at site of injection; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (Redness at site for injection), VACCINATION SITE PAIN (Soreness at site of injection), URTICARIA (Hives), VACCINATION SITE PRURITUS (Itchy area of injection) and VACCINATION SITE WARMTH (hot to touch) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 03-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (Redness at site for injection) and VACCINATION SITE PAIN (Soreness at site of injection). On 11-Jan-2021, the patient experienced URTICARIA (Hives), VACCINATION SITE PRURITUS (Itchy area of injection) and VACCINATION SITE WARMTH (hot to touch). On 05-Jan-2021, VACCINATION SITE ERYTHEMA (Redness at site for injection) and VACCINATION SITE PAIN (Soreness at site of injection) had resolved. At the time of the report, URTICARIA (Hives) and VACCINATION SITE WARMTH (hot to touch) outcome was unknown and VACCINATION SITE PRURITUS (Itchy area of injection) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications was reported. Treatment details include ice pack, Benadryl cream, hydrocortisone cream.; Sender's Comments: Based on the current available information and the temporal association between the product use and the start date of the events a causal relationship cannot be excluded.
Fatigue; Joint pain; This is a spontaneous report from a contactable consumer or other non hcp (patient herself). A 54-years-old female patient received bnt162b2 (BNT162B2, Formulation: Solution for injection, Lot number was not provided, Expiry date: Unknown, Age at vaccination: 54) via an unspecified route of administration in Arm Right on 07Jun2021 as dose 1, single for COVID-19 immunisation. The patient medical history included ongoing diabetes mellitus, it was controlled with diet, ongoing hypothyroidism and high cholesterol. Patient did not receive any other vaccines within 4 weeks prior and other medications 2 weeks prior to the COVID vaccine. Concomitant medications included levothyroxine sodium (SYNTHROID) taken for hypothyroidism from an unspecified start date and ongoing; pravastatin (PRAVASTATIN) taken for blood cholesterol increased from an unspecified start date and ongoing; ergocalciferol (VITAMIN D [ERGOCALCIFEROL]) taken for an unspecified indication from an unspecified start date and ongoing; acetylsalicylic acid (BABY ASPIRIN) taken for an unspecified indication from an unspecified start date and ongoing. The patient experienced fatigue and joint pain on an unspecified date. She has had fatigue for the last 2 or 3 days. Joint pain started 3 or 4 days ago. The seriousness of the events was non-serious. The outcome of the event was not recovered.  Information on the lot/batch number has been requested.er has been requested.
Fever 99.5- 100.3 for about 12 hours.  Chills, muscle aches and pain throughout the body- lasting 5 days Sensitivity to touch.  Extreme lethargy- 5 days. Nausea  Dehydration, craving more water 5 days. Accelerated heart rate day 5, 130-152 bpm
got the shot and still got shingles/suspected vaccination failure; got shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: got the shot and still got shingles/suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: got shingles). The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  It was unknown if the company considered the vaccination failure and shingles to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 12-MAR-2023 This case was reported by a patient's friend via interactive digital media. The patient got the shingles shot and still got shingles. The reporter stated that no thank you and the last two years they had seen how credible science was. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting.  The follow up would not possible as no contact details were available.
First dose of vaccine given in left arm now eight/nine days later there is an itchy rash on this arm below where the vaccine was given. My concern is does she still get the second dose, do we tell who is giving it that there was a reaction to the first dose and if so does she get it in the same arm?